Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Colorcon
Merck
Dow
Baxter

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR CARDENE SR


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Cardene Sr

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00325793 ↗ IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status PDL BioPharma, Inc. Phase 4 2004-01-01 Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00325793 ↗ IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status OSF Healthcare System Phase 4 2004-01-01 Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00528827 ↗ A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of CardeneĀ® I.V. in Pediatric Subjects With Hypertension Withdrawn Facet Biotech Phase 2 2007-09-01 To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cardene Sr

Condition Name

Condition Name for Cardene Sr
Intervention Trials
Hypertension 3
Cerebral Vasospasm 2
Acute Stroke 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cardene Sr
Intervention Trials
Hypertension 3
Vasospasm, Intracranial 2
Cerebral Hemorrhage 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cardene Sr

Trials by Country

Trials by Country for Cardene Sr
Location Trials
United States 17
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cardene Sr
Location Trials
Texas 2
Ohio 2
Florida 2
Illinois 2
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cardene Sr

Clinical Trial Phase

Clinical Trial Phase for Cardene Sr
Clinical Trial Phase Trials
Phase 4 5
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cardene Sr
Clinical Trial Phase Trials
Withdrawn 3
Recruiting 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cardene Sr

Sponsor Name

Sponsor Name for Cardene Sr
Sponsor Trials
Vanderbilt University Medical Center 2
University at Buffalo 1
The Medicines Company 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cardene Sr
Sponsor Trials
Other 21
Industry 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Baxter
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.